PHAT

PhathomB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

Positive clinical readouts and a non-dilutive partnership would materially de-risk the pipeline and support roughly 2x upside from the anchor, consistent with the bull target.

Posture

Constructive

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta +15.3.

What can break

Clinical failure or the need for dilutive financing would compress value toward ~50% of the anchor, consistent with the bear target and a materially lower recovery valuation.

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $15.62 · Bull $31.24 · Bear $7.81

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2025-11-29 • Model: RankAlpha Sentiment AI

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net —

Target $23.70

Why

Momentum29 · Δ7d +12.6

Value41 · Δ7d -0.1

Sentiment95 · Δ7d +15.3

So what

Strength-led posture. Favor watchlist adds and disciplined entries.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Sentiment · See AI snapshot

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+12.6

Δ21d

+32.0

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+15.3

Δ21d

-3.7

Why this grade

Composite grade B. Momentum 29.0 / Value 41.1 / Sentiment 94.9

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$872.53M

Beta

0.52

Shares Out

79.76M

P/E (TTM) · Derived

-3.6

P/S (TTM)

7.65

P/FCF (TTM) · Derived

-8.29

Rev YoY

+104.4%

EPS YoY

-71.8%

Gross Margin

+84.9%

Op Margin

-145.0%

Net Debt

$459.2M

Current Ratio

2.21

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology